66.4 Gender-Affirming Primary Care & Hormone Therapy

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

66.4 Gender-Affirming Primary Care & Hormone Therapy

Key Takeaways Explain This Topic AI

Primary care for transgender and gender-diverse individuals adheres to WPATH SOC 8 and Endocrine Society guidelines, anchoring clinical preventive screening on a rigorous 'Organ Inventory' (if an anatomical organ is present, screen it according to standard organ-specific guidelines regardless of legal sex or gender identity).

Masculinizing hormone therapy elevates serum total testosterone into the normal cisgender male physiological range (300–1000 ng/dL); regular monitoring of hematocrit is mandatory due to erythrocytosis risk (hematocrit >54% necessitates dose reduction, sleep apnea evaluation, or therapeutic phlebotomy to prevent polycythemia-related thrombosis).

CRITICAL REPRODUCTIVE PEARL: Exogenous testosterone is NOT a reliable contraceptive; transgender men with intact internal reproductive organs engaging in receptive penile-vaginal intercourse can become pregnant and must be co-prescribed non-estrogenic contraception (e.g., levonorgestrel IUD, etonogestrel implant, or progestin-only pills).

Feminizing hormone therapy combines 17β-estradiol (oral, transdermal, or IM) with an anti-androgen (spironolactone 100–200 mg daily or cyproterone/finasteride), targeting serum estradiol between 100–200 pg/mL and suppressing total testosterone to cisgender female levels (<50 ng/dL); transdermal estradiol is preferred in patients >40 years, smokers, or those with thromboembolic risk.

Fertility preservation counseling (cryopreservation of oocytes/embryos or spermatozoa) is an ethical imperative that must occur PRIOR to the initiation of gender-affirming hormone therapy, as prolonged gonadal suppression can cause irreversible gametogenic impairment.

Last updated: September 2026

Principles of Affirming Primary Care & The Organ Inventory

Gender-affirming primary care is centered on evidence-based, compassionate, and patient-centered medicine aligned with the World Professional Association for Transgender Health Standards of Care, Version 8 (WPATH SOC 8) and the Endocrine Society Clinical Practice Guidelines . Family physicians serve as the essential clinical coordinators managing hormone therapy, preventive wellness, and routine chronic illness care.

Clinical Environment & Inclusive Documentation

Names and Pronouns : Affirming communication requires consistently using the patient's affirmed name and pronouns (e.g., she/her, he/him, they/them) across oral and electronic medical record (EMR) interactions. EMR systems must decouple demographic fields: legal name, chosen name, legal sex marker, sex assigned at birth, and gender identity.

Trauma-Informed Physical Examination : Invasive examinations (e.g., pelvic exams, breast/chest exams, genital examinations) should be performed only when clinically indicated, with explicit prior explanation, chaperone options, trauma-informed positioning, and smaller pediatric/narrow speculums when severe vaginal atrophy is present.

The "Organ Inventory" Paradigm in Cancer Screening

Routine cancer screening guidelines based strictly on cisgender demographic designations fail to protect transgender patients. The universal primary care principle is:

Important

The Organ Inventory Rule Screen whatever anatomical organs and tissues are present , regardless of the patient's legal sex marker, gender expression, or gender identity:

Cervix Present (transgender men who have not undergone total hysterectomy): Follow standard cervical cancer screening guidelines (cervical cytology and high-risk HPV cotesting). Testosterone therapy often induces cervical atrophy, which can increase the rate of "unsatisfactory for evaluation" Pap results; treating with localized vaginal estrogen for 7–14 days prior to repeat sampling improves cellular yield.

Breast / Chest Tissue Present :

Transgender men who have not had bilateral mastectomy ("top surgery"): Routine screening mammography starting at age 40 (per USPSTF guidelines).

Transgender men post-mastectomy: If residual breast tissue remains, perform annual clinical chest exams.

Transgender women receiving feminizing hormone therapy: After ≥5–10 years of feminizing hormone therapy and reaching age 50, initiate biennial screening mammography due to estrogen-induced breast lobuloalveolar development.

Prostate Present (transgender women, regardless of whether they have undergone vaginoplasty/orchiectomy): Transgender women retain their prostate gland (the prostate is not removed during gender-affirming vaginoplasty). Engage in shared decision-making regarding PSA screening starting at age 50 (or 40–45 if African American or positive family history). Diagnostic Nuance : Normal female reference ranges for PSA should be used; because anti-androgens and estrogens suppress baseline PSA by approximately 50%, a PSA value > 1.0 ng/mL >1.0\text{ ng/mL} > 1.0 ng/mL in a transfeminine patient on hormone suppression warrants urologic investigation.

Gender-Affirming Hormone Therapy (GAHT)

The goal of gender-affirming hormone therapy is to induce secondary sexual characteristics concordant with the patient's affirmed gender while suppressing incongruent endogenous sexual characteristics, keeping systemic hormone concentrations within normal physiological reference ranges for the affirmed gender.

1. Feminizing Hormone Therapy (Transgender Women / Transfeminine Individuals)
Therapeutic Goals

Suppress endogenous testosterone to the physiological cisgender female range: Total Testosterone < 50 ng/dL < 50\text{ ng/dL} < 50 ng/dL .

Maintain physiological cisgender female estradiol levels: Serum Estradiol 100 to 200 pg/mL 200\text{ pg/mL} 200 pg/mL .

Clinical phenotypic changes: Breast development (typically Tanner stage II–III), female body fat redistribution (increased hip/buttock fat, decreased abdominal visceral fat), skin softening, decreased facial/body hair growth rate, decreased spontaneous erections and testicular volume, and reduction in androgenic male-pattern balding. FEMINIZING HORMONE THERAPY: DRUGS & DOSAGES

Drug Class & Agent Route & Typical Daily Dose Clinical Advantages & Monitoring Pearls

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

17β-Estradiol (Oral) • 2.0 to 8.0 mg PO once daily • Low cost; well tolerated.

(or divided twice daily; can be • Undergoes hepatic first-pass metabolism;

administered sublingually) modest increases in VTE risk in older smokers.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

17β-Estradiol • 0.1 to 0.4 mg/day patch applied • PREFERRED FIRST-LINE FOR:

(Transdermal Patch) once or twice weekly - Age > 40 years, tobacco users, obesity
Controlled hypertension, hypertriglyceridemia

- Personal/family risk factors for VTE.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Estradiol Valerate or • 10 to 20 mg IM or subcutaneous • Avoids daily dosing; provides rapid peak

Estradiol Cypionate every 1 to 2 weeks estradiol concentrations.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Spironolactone • 100 to 200 mg PO daily in • FIRST-LINE ANTI-ANDROGEN IN THE UNITED STATES.

(Anti-Androgen) divided doses (50–100 mg BID) • Blocks androgen receptors; inhibits 17α-hydroxylase.

• ADVERSE EFFECTS: Hyperkalemia, polyuria, orthostasis.

• MANDATORY: Monitor K+ and Cr at baseline and q3mo.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Finasteride / • Finasteride 1 to 5 mg PO daily • 5α-reductase inhibitor; blocks DHT synthesis.

Dutasteride Dutasteride 0.5 mg PO daily • Useful adjuvant for androgenic alopecia;

does NOT lower total testosterone levels.

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Laboratory Monitoring in Feminizing GAHT :

Check serum estradiol , total testosterone , basic metabolic panel (potassium, BUN, creatinine) , and blood pressure every 3 months during the first year , then every 6 to 12 months once stable.

Target: Estradiol 100 – 200 pg/mL 100–200\text{ pg/mL} 100–200 pg/mL (measure at trough if receiving IM injections; avoid drawing blood immediately after sublingual dosing to prevent falsely high spikes).

Target: Total testosterone < 50 ng/dL <50\text{ ng/dL} < 50 ng/dL .

Routine serum prolactin is checked at baseline and periodically if the patient develops galactorrhea, visual changes, or headaches (estrogen stimulates pituitary lactotroph hyperplasia; rare prolactinoma).

2. Masculinizing Hormone Therapy (Transgender Men / Transmasculine Individuals)
Therapeutic Goals

Elevate serum total testosterone to the physiological cisgender male range: 300 to 1000 ng/dL 1000\text{ ng/dL} 1000 ng/dL .

Suppress endogenous ovarian estradiol production.

Clinical phenotypic changes:

Irreversible Changes : Deepening of vocal pitch (vocal cord hypertrophy), clitoromegaly (typically 1–4 cm enlargement), facial and terminal body hair growth, and androgenic male-pattern temporal hair thinning.

Reversible Changes : Cessation of menses (amenorrhea typically occurs within 2–6 months), increased lean skeletal muscle mass and strength, upper-body fat redistribution, increased libido, and acne. MASCULINIZING HORMONE THERAPY: DRUGS & DOSAGES

Formulation & Agent Route & Typical Dosage Clinical Administration & Pharmacokinetics

Testosterone Cypionate • 50 to 100 mg Subcutaneous • Weekly administration provides smoother serum levels

or Enanthate or IM once weekly, OR with fewer emotional or energy fluctuations.

• 100 to 200 mg IM every 2 weeks • Subcutaneous injection is equally effective as IM

and causes significantly less injection discomfort.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Transdermal • 50 to 100 mg (1–2 pumps) • Applied topically every morning to clean, dry skin

Testosterone Gel (1–1.62%) applied to shoulders/upper arms of shoulders or upper arms (NEVER genitals).

• RISK OF INTERPERSONAL TRANSFER: Must wash hands

and cover area; keep away from children/partners.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Testosterone Undecanoate • 750 mg IM at 0, 4 weeks, • Long-acting depot formulation; provides stable

(Aveed) then every 10 weeks levels for months; boxed warning for PEMA (microembolism).

Laboratory Monitoring & The Erythrocytosis Imperative

Total Testosterone Monitoring : Measured every 3 months during the first year , then every 6 to 12 months .

For weekly injections: Check midway between injections (trough/mid-cycle; target 400 – 700 ng/dL 400–700\text{ ng/dL} 400–700 ng/dL ) or at trough just prior to the next injection ( > 300 – 400 ng/dL >300–400\text{ ng/dL} > 300–400 ng/dL ).

For transdermal gel: Check 2 to 8 hours after morning application.

Hematocrit & Hemoglobin Monitoring (Critical ABFM Concept) :

Testosterone directly stimulates renal erythropoietin (EPO) production and bone marrow erythropoiesis, while suppressing hepcidin (increasing iron availability).

Secondary Erythrocytosis (Polycythemia) is the most common dose-limiting adverse effect of testosterone therapy, occurring in up to 10–15% of patients.

Management Algorithm for Erythrocytosis :

Hematocrit ≤ 50 % \le 50\% ≤ 50% : Normal male range; continue maintenance regimen.

Hematocrit 50 % − 54 % 50\% - 54\% 50% − 54% : Borderline elevation; monitor closely every 3 months; encourage smoking cessation and hydration; screen for obstructive sleep apnea.

Hematocrit > 54 % > 54\% > 54% : CRITICAL THRESHOLD . Markedly increases blood viscosity, microcirculatory sluggishness, and the risk of fatal ischemic stroke, deep vein thrombosis, and myocardial infarction.

Mandatory Clinical Interventions for Hct > 54 % > 54\% > 54% :

Reduce testosterone dosage by 25–50% or switch from injectable depot to transdermal daily gel.

Screen for and aggressively treat concurrent Obstructive Sleep Apnea (OSA) (testosterone worsens nocturnal airway collapse).

Perform therapeutic phlebotomy (500 mL) if hematocrit remains > 54 % >54\% > 54% despite dose reduction, to immediately restore safe rheology.

Metabolic & Hepatic Monitoring : Check fasting lipid profile (testosterone may lower HDL and slightly increase LDL/triglycerides), liver biochemistries, and blood pressure at baseline and annually.

Reproductive Health & Fertility Counseling
1. Mandatory Fertility Preservation Counseling

Gender-affirming hormone therapies suppress the hypothalamic-pituitary-gonadal axis, leading to testicular atrophy and azoospermia in transfeminine individuals, and follicular arrest and amenorrhea in transmasculine individuals. While these effects are sometimes reversible upon medication discontinuation, long-term GAHT can cause permanent, irreversible germ cell damage and infertility.

Guideline Mandate : Clinicians MUST discuss reproductive wishes and offer referrals for fertility preservation PRIOR to the initiation of any gender-affirming hormone therapy or gonadectomy .

Options include:

For transfeminine individuals: Semen cryopreservation (sperm banking).

For transmasculine individuals: Oocyte or embryo cryopreservation (requires ovarian stimulation and transvaginal ultrasound-guided oocyte retrieval).

2. The Critical Contraceptive Rule: Testosterone is NOT Birth Control

[!CRITICAL] Testosterone is NOT a Contraceptive Although exogenous testosterone therapy induces amenorrhea in > 90 % >90\% > 90% of transmasculine individuals within 3 to 6 months, intermittent, spontaneous ovulation CAN STILL OCCUR .

Transgender men with an intact uterus and ovaries who engage in receptive penile-vaginal intercourse with sperm-producing partners are at significant risk for unintended pregnancy .

Furthermore, exogenous testosterone is a potent teratogen causing virilization of a female fetus, craniofacial defects, and pregnancy loss.

First-Line Contraceptive Options for Transmasculine Patients :

Levonorgestrel-releasing Intrauterine System (LNG-IUD) : First-line; provides exceptionally high contraceptive efficacy ( > 99.8 % >99.8\% > 99.8% ), induces local endometrial decidualization, synergistically accelerates amenorrhea, and produces negligible systemic progestin levels that do NOT interfere with masculinization.

Copper Intrauterine Device (Cu-IUD) : 100% hormone-free; highly effective; may cause increased cramping or breakthrough spotting.

Etonogestrel Subdermal Implant (Nexplanon) : Progestin-only; excellent efficacy for 3–5 years; does not interfere with testosterone.

Progestin-Only Oral Pills (POPs; e.g., drospirenone or norethindrone) : Safe and effective without estrogenic vascular risks.

Note : Estrogen-containing combined hormonal contraceptives (COCs, patch, ring) are generally avoided due to dysphoria and physiological feminization, although they are not medically contraindicated if patient prefers.